Pfizer Inc. which can be found using ticker (PFE) now have 24 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $45.00 and $25.00 calculating the average target price we see $32.55. Given that the stocks previous close was at $24.80 this now indicates there is a potential upside of 31.3%. Also worth taking note is the 50 day moving average now sits at $28.55 and the 200 day moving average is $28.14. The company has a market cap of 140.88B. The current share price for the company is: $24.86 USD
The potential market cap would be $184,897,323,598 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 33.15, revenue per share of $10.49 and a 3.31% return on assets.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
